Connect your AI

Arrowhead Research ARWR Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Ionis PharmaceuticalsIONS

-$98.27M+32.3%

Regeneron PharmaceuticalsREGN

$661.6M-21.8%

ALN

Alnylam PharmaceuticalsALNY

——

RevvityRVTY

——

Neurocrine BiosciencesNBIX

——

Other financials

Income statement

Revenue$73.7M-86.4%

Operating income-$141.3M-137%

Net income-$132.7M-136%

EPS (diluted)-$0.93-134%

Balance sheet

Cash & equivalents$188.5M+1.5%

Total debt$107.9M-5.6%

Total equity$614.0M-10.1%

Total assets$2.3B+44.2%

Cash flow

Operating cash flow$84.4M-81.6%

CapEx$2.6M-51.6%

Free cash flow$81.9M-82.0%

Valuation

Market cap$11.52B+402%

Enterprise value$11.44B+418%

P/S18.5×+14.3×

Profitability

Operating margin-35.7%+63.6pp

Net margin-48.4%+240pp

FCF margin1.8%+0.9pp

Returns & leverage

Return on equity-46.4%+341pp

Debt / equity0.2×0.0×

Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Arrowhead Research's comprehensive income (loss), net of tax, attributable to parent?: Arrowhead Research (ARWR) reported comprehensive income (loss), net of tax, attributable to parent of -$139.09M in Q1 2026.
How has Arrowhead Research's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?: Arrowhead Research's comprehensive income (loss), net of tax, attributable to parent decreased by 137.5% year-over-year, from $370.7M to -$139.09M.